TMED2 and neoplasm: To further confirm the tumor-inhibition effect of TMED2 and whether it was mediated through the TLR4/NF-κB signaling pathway, we used an activator of TLR4 (sparstolonin B) to boost TLR4 expression and observed the changes in the downstream inflammatory factors using western blotting (Fig. 6).